{
    "clinical_study": {
        "@rank": "26724", 
        "arm_group": [
            {
                "arm_group_label": "Second HBV vaccination cycle", 
                "arm_group_type": "Experimental", 
                "description": "Second cycle of HBV vaccination (0, 1 and 2 months)will be administered. Three intramuscular doses of 40 \u00b5g."
            }, 
            {
                "arm_group_label": "Single dose of HBV vaccine", 
                "arm_group_type": "Active Comparator", 
                "description": "Single dose (40\u00b5g) of HBV vaccine will be administered at 6 months after 1 cycle of HBV vaccination"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this clinical trial is to compare the response rate obtained with two\n      different vaccination schemes against HBV in cirrhotic patients. These patients must be\n      candidates for liver transplantation, who have failed seroconversion (anti-HBs < 10 IU/ml)\n      after three intramuscular doses of 40 \u00b5g."
        }, 
        "brief_title": "Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatitis B", 
            "Cirrhosis", 
            "Awaiting Organ Transplant"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Liver Cirrhosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Cirrhotic patients, potential candidates for liver transplantation, with indication\n             to HBV vaccination (HBsAg negative and anti-HBs negative).\n\n          2. Patients under treatment with HBVAXPRO\u00ae who do not show a response after the first\n             cycle of vaccination of three intramuscular doses of 40 \u00b5g at 0, 1 and 2 months.\n\n          3. Patients over 18 years old.\n\n          4. Negative pregnancy test.\n\n          5. Patients who have given their consent to participate in the study.\n\n        Exclusion Criteria:\n\n          1. Absolute contraindication to HBV vaccine.\n\n          2. Medical history of allergy to any component of the vaccine.\n\n          3. Chronic renal failure on hemodialysis.\n\n          4. Presence of antibodies against Human Immunodeficiency Virus.\n\n          5. Patients with seroconversion (anti-HBs > 10 IU /ml) after the first three doses of\n             vaccine.\n\n          6. Lack of consent to participate in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884415", 
            "org_study_id": "HEPATOTRAS"
        }, 
        "intervention": [
            {
                "arm_group_label": "Second HBV vaccination cycle", 
                "description": "Patients receive a second cycle of vaccination", 
                "intervention_name": "HBV vaccine", 
                "intervention_type": "Biological", 
                "other_name": "HBVAXPRO 40\u00b5g HBV vaccine"
            }, 
            {
                "arm_group_label": "Single dose of HBV vaccine", 
                "description": "Patients receive vaccination according to the guidelines.", 
                "intervention_name": "HBV vaccine", 
                "intervention_type": "Biological", 
                "other_name": "HBVAXPRO 40\u00b5g HBV vaccine"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 13, 2014", 
        "location": {
            "contact": {
                "email": "claram.rosso.sspa@juntadeandalucia.es", 
                "last_name": "Clara M. Rosso Fern\u00e1ndez, MD", 
                "phone": "0034 955 01 34 14"
            }, 
            "contact_backup": {
                "email": "jmpascasio@gmail.com", 
                "last_name": "Juan Manuel Pascasio Acevedo, MD, PhD", 
                "phone": "0034 955 01 22 50"
            }, 
            "facility": {
                "address": {
                    "city": "Seville", 
                    "country": "Spain", 
                    "zip": "41013"
                }, 
                "name": "Virgen del Roc\u00edo Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Juan Manuel Pascasio Acevedo, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "\u00c1lvaro Giraldez Gallego, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mar\u00eda Teresa Ferrer R\u00edos, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Raquel Valencia Mart\u00edn, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jos\u00e9 Manuel Sousa Mart\u00edn, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Open-label, Phase III, Randomized, Clinical Trial to Evaluate the Efficacy of Two Different Hepatitis B Virus (HBV) Vaccination Schemes in Patients With Hepatic Cirrhosis Candidates to Liver Transplantation", 
        "overall_contact": {
            "email": "claram.rosso.sspa@juntadeandalucia.es", 
            "last_name": "Clara M. Rosso Fern\u00e1ndez, MD", 
            "phone": "0034 955 01 34 14"
        }, 
        "overall_contact_backup": {
            "email": "jmpascasio@gmail.com", 
            "last_name": "Juan Manuel Pascasio Acevedo, MD, PhD", 
            "phone": "0034 955 31 22 50"
        }, 
        "overall_official": {
            "affiliation": "Virgen del Roc\u00edo Hospital", 
            "last_name": "Juan Manual Pascasio Acevedo, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the response rate obtained with two different vaccination schemes against HBV in cirrhotic patients potential candidates for liver transplantation, who have failed seroconversion (anti-HBs < 10 IU/ml) after three intramuscular doses of 40 \u00b5g  at 0, 1 and 2 months.", 
            "measure": "Post-vaccination serological response", 
            "safety_issue": "No", 
            "time_frame": "At 35 \u00b1 5 days after administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884415"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Etiology and severity of cirrhosis", 
                "measure": "Association of serological response to HBV vaccination to other clinical variables", 
                "safety_issue": "Yes", 
                "time_frame": "After 6 months"
            }, 
            {
                "description": "Diabetes", 
                "measure": "Association of serological response to HBV vaccination to other clinical variables", 
                "safety_issue": "Yes", 
                "time_frame": "After 6 months"
            }, 
            {
                "description": "Body mass index", 
                "measure": "Association of serological response to HBV vaccination to other clinical variables", 
                "safety_issue": "No", 
                "time_frame": "At baseline"
            }, 
            {
                "description": "Presence of anti-Hepatitis B core antigen positive", 
                "measure": "Association of serological response to HBV vaccination to other clinical variables", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline"
            }, 
            {
                "description": "Obesity", 
                "measure": "Association of serological response to HBV vaccination to other clinical variables", 
                "safety_issue": "No", 
                "time_frame": "After 6 months"
            }
        ], 
        "source": "Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Investigaci\u00f3n en Sevilla", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Investigaci\u00f3n en Sevilla", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}